Patents by Inventor Laurence Cooper
Laurence Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200017882Abstract: Human or humanized tissues and organs suitable for transplant are disclosed herein. Gene editing of a host animal provides a niche for complementation of the missing genetic information by donor stem cells. Editing of a host genome to knock out or disrupt genes responsible for the growth and/or differentiation of a target organ and injecting that animal at an embryo stage with donor stem cells to complement the missing genetic information for the growth and development of the organ. The result is a chimeric animal in which the complemented tissue (human/humanized organ) matches the genotype and phenotype of the donor. Such organs may be made in a single generation and the stem cell may be taken or generated from the patient's own body. As disclosed herein, it is possible to do so by simultaneously editing multiple genes in a cell or embryo creating a “niche” for the complemented tissue.Type: ApplicationFiled: April 16, 2019Publication date: January 16, 2020Inventors: Scott C. Fahrenkrug, Laurence Cooper, Perry B. Hackett, Daniel F. Carlson
-
Patent number: 10261242Abstract: An optical fiber package is described comprising a light transmitting core having a core diameter, a coating layer surrounding the core, and wherein the amount of chlorine in the light transmitting core region is homogeneous and comprises at least 3000 ppm. The fiber package is such that the optical fiber core exhibits a reduction in the hydrogen induced attenuation losses. A method for fabricating the optical fiber package is also disclosed.Type: GrantFiled: May 21, 2015Date of Patent: April 16, 2019Assignee: Fibercore LimitedInventors: Christopher Emslie, Peter Maton, Laurence Cooper, Aurélien Bergonzo
-
Publication number: 20180243340Abstract: In some embodiments, the present disclosure pertains to a method of enhancing chimeric antigen receptor expressing T cell function. In some embodiments, the method comprises activating the chimeric antigen receptor expressing T cells. In some embodiments, the method further comprises determining the differential expression of at least one molecule on the chimeric antigen receptor T cells. In some embodiments, the method comprises targeting the at least one molecule. In some embodiments, the present disclosure pertains to a method of treating a tumor in a subject in need thereof. In some embodiments, the method comprises administering to the subject an infusion of chimeric antigen receptor expressing T cells. In some embodiments, the method further comprises determining the differential expression of at least one molecule on the chimeric antigen receptor T cells.Type: ApplicationFiled: August 23, 2016Publication date: August 30, 2018Applicant: University of Houston SystemInventors: Navin Varadarajan, Gabrielle Romain, Laurence Cooper, Harjcct Singh
-
Publication number: 20170205574Abstract: An optical fiber package is described comprising a light transmitting core having a core diameter, a coating layer surrounding the core, and wherein the amount of chlorine in the light transmitting core region is homogeneous and comprises at least 3000 ppm. The fiber package is such that the optical fiber core exhibits a reduction in the hydrogen induced attenuation losses. A method for fabricating the optical fiber package is also disclosed.Type: ApplicationFiled: May 21, 2015Publication date: July 20, 2017Applicant: Fibercore LimitedInventors: Christopher EMSLIE, Peter MATON, Laurence COOPER, Aurélien BERGONZO
-
Publication number: 20170152526Abstract: Human or humanized tissues and organs suitable for transplant are disclosed herein. Gene editing of a host animal provides a niche for complementation of the missing genetic information by donor stem cells. Editing of a host genome to knock out or disrupt genes responsible for the growth and/or differentiation of a target organ and injecting that animal at an embryo stage with donor stem cells to complement the missing genetic information for the growth and development of the organ. The result is a chimeric animal in which the complemented tissue (human/humanized organ) matches the genotype and phenotype of the donor. Such organs may be made in a single generation and the stem cell may be taken or generated from the patient's own body. As disclosed herein, it is possible to do so by simultaneously editing multiple genes in a cell or embryo creating a “niche” for the complemented tissue.Type: ApplicationFiled: October 27, 2016Publication date: June 1, 2017Inventors: Scott C. Fahrenkrug, Laurence Cooper, Perry B. Hackett, Daniel F. Carlson
-
Publication number: 20150297640Abstract: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.Type: ApplicationFiled: November 17, 2014Publication date: October 22, 2015Inventors: Laurence Cooper, Michael C. Jensen
-
Publication number: 20130149337Abstract: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.Type: ApplicationFiled: September 29, 2011Publication date: June 13, 2013Applicant: CITY OF HOPEInventors: LAURENCE COOPER, MICHAEL JENSEN
-
Publication number: 20090191172Abstract: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.Type: ApplicationFiled: March 5, 2009Publication date: July 30, 2009Applicant: City of HopeInventors: Laurence Cooper, Michael Jensen
-
Publication number: 20070166327Abstract: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to viral specific T cells that express chimeric anti-tumor receptors. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.Type: ApplicationFiled: February 1, 2007Publication date: July 19, 2007Applicant: City of HopeInventors: Laurence Cooper, Michael Jensen
-
Publication number: 20070036773Abstract: The present invention is directed to universal T cells and their use in treating diseases and other physiological conditions. More specifically, the present invention is directed to universal T cells and their use in treating treating B-lineage acute lymphoblastic leukemia (B-ALL) in particular and malignancy in general. The universal T cells contain (i) nucleic acid encoding a chimeric antigen receptor (CAR) to redirect their antigen specificity and effector function and (ii) nucleic acids encoding shRNA and/or siRNA molecules to down-regulate cell-surface expression of T cell classical HLA class I and/or II genes to avoid recognition by recipient T cells. The universal T cells may also contain a nucleic acid encoding a non-classical HLA gene, such as an HLA E gene to enforce expression of HLA E genes and/or an HLA G gene to enforce expression of HLA G genes, to avoid recognition by recipient NK cells. The universal T cells may further contain a nucleic acid encoding a selection-suicide gene.Type: ApplicationFiled: August 8, 2006Publication date: February 15, 2007Applicant: City of HopeInventors: Laurence Cooper, John Rossi
-
Publication number: 20060018878Abstract: The present invention is directed to mammalian T cells and methods for using these T cells. More specifically, the invention relates to viral specific T cells that express an endogenous viral antigen receptor, a chimeric anti-tumor receptor and the chemokine receptor CCR7. These T cells are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases and that are able to traffic to lymph nodes and sites of minimal residual disease.Type: ApplicationFiled: July 21, 2005Publication date: January 26, 2006Applicant: City of HopeInventors: Laurence Cooper, Zaid Al-Kadhimi
-
Publication number: 20050227940Abstract: Methods for amplifying expression of interfering RNA (RNAi), and preferably siRNA or shRNA, using a RNAi (si/shRNA)-expressing concatamer, are disclosed. The methods are useful for modulating, including down-regulating and/or inhibiting, expression of a target gene in cells, including mammalian cells.Type: ApplicationFiled: January 24, 2005Publication date: October 13, 2005Applicant: City of HopeInventors: John Rossi, Daniela Castanotto, Laurence Cooper, Sergio Gonzalez
-
Publication number: 20050129671Abstract: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to viral specific T cells that express chimeric anti-tumor receptors. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases.Type: ApplicationFiled: March 11, 2004Publication date: June 16, 2005Applicant: City of HopeInventors: Laurence Cooper, Michael Jensen